Novo Nordisk narrowed its earnings guidance as intensifying competition, pricing pressure and copycat versions of its ...

ADP private payrolls took center stage as the US shutdown, which has stifled the flow of official data, became the longest ...

Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company ...

As Novo Nordisk fights a bidding war against Pfizer to acquire the obesity biotech Metsera, its new CEO dismissed claims that ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill ...

Novo Nordisk stock just crashed -- but new drugs, smart acquisitions, and Wall Street upgrades could set up one of the biggest pharma rebounds of 2026.

Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to ...

The Dow, S&P 500, and Nasdaq are falling little changed as the stock market digests yesterday's tech-led selloff.

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.